<DOC>
	<DOCNO>NCT02112981</DOCNO>
	<brief_summary>meriT-V Prospective , active control open lable clinical trial compare safety &amp; efficacy BioMime Sirolimus stent Vs. Xience family Everolimus stent random assignment treatment coronary artery disease multiple multinational centre .</brief_summary>
	<brief_title>BioMime Vs. Xience Randomised Control Clinical Study</brief_title>
	<detailed_description>This study conduct evaluate multicenter investigation compare BioMime Sirolimus Drug Eluting stent XIENCE family ( Abbott Vascular , Santa Clara , California , USA ) treatment patient coronary artery disease . Considering randomized study provide good comparability real efficacy safety data device . Subjects randomize 2:1 surrogate endpoint clinical evaluation . Subject include study eligible meet inclusion exclusion criterion study protocol .The informed consent process perform subject underwent Procedure . Subject treat treatment allocated process Randomization . The study follow Seattle angina score evaluation 2 year procedure angioplasty along Hospital telephonic follow 1 Month 5month ,1 2 year angiographic follow 9 Month .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>The patient must ≥18 year age . Clinical evidence ischemic heart disease and/or positive territorial functional study . Documented stable angina pectoris ( Canadian Cardiovascular Society ( CCS ) Classification 1 , 2 , 3 4 ) unstable angina pectoris document ischemia ( Braunwald Class IBC , IIBC , IIIBC ) , document silent ischemia The patient plan intervention two denovo native lesion Target lesion reference diameter ≥ 2.5 mm ≤ 3.5 mm diameter ( visually estimate ) The target lesion length less equal 46 mm ( visually estimate ) Patient willing provide write informed consent . If patient female , without childbearing potential undergone surgical sterilization postmenopausal . The patient patient 's physician agree followup visit include 9 month angiographic followup . Evidence acute Qwave nonQwave myocardial infarction within 72 hour precede index procedure , unless CK CKMB enzymes less twice Upper Normal Limit . The patient know hypersensitivity contraindication requisite medication include aspirin , heparin , clopidogrel , prasugrel , ticagrelor , sirolimus , everolimus . There untreated significant lesion &gt; 40 % diameter stenosis remain proximal distal target site plan intervention . Previous placement stent target lesion and/or within 10 mm target lesion . Lesion significant side branch ( branch diameter &gt; 2 mm ) would cover stenting Total occlusion TIMI 0 coronary flow target vessel . Left Main coronary artery disease ( stenosis &gt; 50 % ) The proximal target vessel target lesion severely calcify visual assessment . Aortoostial location , unprotected leave main lesion location , lesion within 5 mm origin LAD LCX . The patient history bleed diathesis coagulopathy refuse blood transfusion The patient suffer stroke , transient ischemic neurological attack ( TIA ) significant gastrointestinal ( GI ) bleed within past 6 month The patient renal insufficiency determine creatinine &gt; 2.0mg/dl 180 µmol/l . The target lesion , target vessel proximal target lesion contain thrombus Documented leave ventricular ejection fraction ≤30 % The patient recipient heart transplant The patient extensive peripheral vascular disease precludes safe 6 French sheath insertion extreme angulation vessel accesslocation ( &lt; 45 degree ) The patient medical illness ( i.e. , cancer congestive heart failure ) may cause patient noncompliant protocol , confound data interpretation associate limited life expectancy ( i.e. , less one year ) The patient simultaneously participate another investigational device drug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>CORONARY ARTERIOSCLEROSIS</keyword>
</DOC>